Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Nephrology · Hereditary Hypophosphatemic Rickets with Hypercalciuria

The Biology of Phosphate Wasting: How Your Genes Affect Your Kidneys

At a Glance

HHRH and NPHLOP1 are inherited disorders in which the kidneys lose too much phosphate. This can raise active vitamin D and urine calcium, causing bone problems, kidney stones, and calcium deposits in the kidneys; oral phosphate is usually used, while active vitamin D is generally avoided.

To understand Hereditary Hypophosphatemic Rickets with Hypercalciuria (HHRH) and NPHLOP1, it helps to think of your kidneys as a recycling center. In a healthy body, the kidneys filter your blood but work hard to “recapture” vital minerals like phosphate so they don’t end up in your urine. In these conditions, the “recapturing machines” are broken, leading to a biological chain reaction that affects your blood, your bones, and your kidneys [1][2].

The Genetic Blueprint: SLC34A3 and SLC34A1

Your body uses specific genes as blueprints to build phosphate transporters in the kidney. When these genes have mutations, the transporters do not function correctly:

  • SLC34A3 (HHRH): This gene builds a transporter called NPT2c. Biallelic mutations (two copies) here cause the classic HHRH phenotype. While it is usually “recessive”, even “carriers” with one mutated copy (monoallelic) can have higher rates of kidney stones and high urine calcium [3][4].
  • SLC34A1 (NPHLOP1): This gene builds a transporter called NPT2a. Heterozygous mutations (one copy) here cause NPHLOP1. While the name is different, the core problem—leaking phosphate—is similar [5][6].

The Biological Cascade: A Chain Reaction

When these transporters (NPT2a or NPT2c) fail, they create a “cascade” effect throughout your body. It is not just a kidney problem; it is a whole-body mineral imbalance:

  1. The Leak: Your kidneys fail to reabsorb phosphate, letting it spill into your urine. This causes low phosphate levels in your blood (hypophosphatemia) [1].
  2. The Compensatory Surge: Your body senses the low phosphate and tries to fix it. It suppresses hormones like FGF23 and keeps PTH (parathyroid hormone) low or low-normal. This signal tells your kidneys to increase production of 1,25-dihydroxyvitamin D (the active form of vitamin D) to help absorb more phosphate from your food [2][7].
  3. The Calcium Burden: Unfortunately, active vitamin D is very “greedy.” While it tries to grab phosphate from your gut, it also grabs extra calcium. While your blood calcium levels generally stay in the normal range, your body must process this excess calcium [3].
  4. The Kidney Burden: Because your PTH levels are low, your kidneys lose their ability to hold onto calcium. The excess calcium from your gut is dumped into your urine (hypercalciuria). This excess calcium in the urinary tract is what causes painful kidney stones and calcium deposits in the kidney tissue (nephrocalcinosis) [3][7].

Why the Distinction Matters: HHRH vs. XLH

It is vital to distinguish HHRH and NPHLOP1 from other phosphate-wasting conditions like X-Linked Hypophosphatemia (XLH). While both cause low phosphate and bone issues, their mechanisms require very different treatments [8].

Simplified Untreated Diagnostic Patterns:

Feature HHRH / NPHLOP1 (FGF23-Independent) XLH (FGF23-Mediated)
Active Vitamin D High or Inappropriately Normal Low or Inappropriately Normal
Urine Calcium High (Hypercalciuria) Low to Normal
PTH Levels Low or Low-Normal Normal to High
FGF23 Appropriately Low Inappropriately High
Typical Treatment Oral Phosphate (calcitriol avoided) Burosumab OR Phosphate + Calcitriol

The Danger of the Wrong Treatment

In many types of rickets (like XLH), doctors routinely prescribe active vitamin D (calcitriol or alfacalcidol). However, in HHRH or NPHLOP1, your active vitamin D is already naturally elevated [3][9].

Giving active vitamin D to someone with confirmed HHRH is generally contraindicated. It can increase the calcium absorption in your gut, worsening hypercalciuria and raising the risk of kidney stones and nephrocalcinosis [10][3]. Note: Never stop or change a prescribed medication on your own. If you are taking active vitamin D and suspect you have HHRH, contact your prescribing team or a metabolic-bone specialist to review your diagnosis [11].

Common questions in this guide

What causes HHRH and NPHLOP1?
HHRH usually occurs when both copies of SLC34A3 are altered; this gene makes the kidney phosphate transporter NPT2c. NPHLOP1 is associated with a change in one copy of SLC34A1, which makes NPT2a. In both disorders, the kidneys reabsorb too little phosphate, so too much is lost in urine.
Why can HHRH or NPHLOP1 lead to kidney stones?
When phosphate is lost, the body increases active vitamin D to improve phosphate absorption from food. Active vitamin D also increases calcium absorption, and low PTH reduces the kidneys’ ability to retain calcium. The excess calcium leaves in urine, causing high urine calcium, kidney stones, and calcium deposits in kidney tissue.
Which tests help distinguish HHRH or NPHLOP1 from XLH?
Doctors often compare phosphate with PTH, FGF23, active vitamin D (1,25-dihydroxyvitamin D), and urine calcium. HHRH and NPHLOP1 typically show high or inappropriately normal active vitamin D, high urine calcium, low or low-normal PTH, and appropriately low FGF23. XLH more often has low or inappropriately normal active vitamin D, low-to-normal urine calcium, normal-to-high PTH, and inappropriately high FGF23.
Why can calcitriol be harmful in HHRH?
In HHRH and NPHLOP1, active vitamin D is often already elevated. Adding calcitriol or alfacalcidol can increase calcium absorption and worsen high urine calcium, kidney stones, or nephrocalcinosis. Do not start, stop, or change these medicines without guidance from the prescribing clinician.
Can someone with one SLC34A3 change have a higher risk of kidney stones?
Yes. People with one altered copy of SLC34A3 may have higher urine calcium and more kidney stones even if they do not have the classic two-copy form of HHRH. A clinician can discuss whether family history and genetic evaluation are appropriate.
How is HHRH usually treated?
Oral phosphate is the usual treatment described for HHRH and NPHLOP1, with care tailored and monitored by a metabolic-bone or kidney specialist. Active vitamin D medicines such as calcitriol are generally avoided because they may worsen high urine calcium. XLH follows a different treatment approach.

Get notified when new evidence is published on nephrolithiasis/osteoporosis, hypophosphatemic.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    Inherited non-FGF23-mediated phosphaturic disorders: A kidney-centric review.

    Walker E, Hayes W, Bockenhauer D

    Best practice & research. Clinical endocrinology & metabolism 2024; (38(2)):101843 doi:10.1016/j.beem.2023.101843.

    PMID: 38042745
  2. 2

    Autosomal-Recessive Mutations in SLC34A1 Encoding Sodium-Phosphate Cotransporter 2A Cause Idiopathic Infantile Hypercalcemia.

    Schlingmann KP, Ruminska J, Kaufmann M, et al.

    Journal of the American Society of Nephrology : JASN 2016; (27(2)):604-14 doi:10.1681/ASN.2014101025.

    PMID: 26047794
  3. 3

    Hereditary hypophosphatemic rickets with hypercalciuria: pathophysiology, clinical presentation, diagnosis and therapy.

    Bergwitz C, Miyamoto KI

    Pflugers Archiv : European journal of physiology 2019; (471(1)):149-163 doi:10.1007/s00424-018-2184-2.

    PMID: 30109410
  4. 4

    Hereditary Hypophosphatemic Rickets with Hypercalciuria Presenting with Enthesopathy, Renal Cysts, and High Serum c-Terminal FGF23: Single-Center Experience and Systematic Review.

    Dodamani MH, Memon SS, Karlekar M, et al.

    Calcified tissue international 2024; (114(2)):137-146 doi:10.1007/s00223-023-01156-2.

    PMID: 37981601
  5. 5

    Digenic Heterozygous Mutations in SLC34A3 and SLC34A1 Cause Dominant Hypophosphatemic Rickets with Hypercalciuria.

    Gordon RJ, Li D, Doyle D, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(7)) doi:10.1210/clinem/dgaa217.

    PMID: 32311027
  6. 6

    Renal phosphate handling and inherited disorders of phosphate reabsorption: an update.

    Wagner CA, Rubio-Aliaga I, Hernando N

    Pediatric nephrology (Berlin, Germany) 2019; (34(4)):549-559 doi:10.1007/s00467-017-3873-3.

    PMID: 29275531
  7. 7

    An update on clinical presentation and responses to therapy of patients with hereditary hypophosphatemic rickets with hypercalciuria (HHRH).

    Zhu Z, Bo-Ran Ho B, Chen A, et al.

    Kidney international 2024; (105(5)):1058-1076 doi:10.1016/j.kint.2024.01.031.

    PMID: 38364990
  8. 8

    FGF23-Mediated Hypophosphatemic Rickets: Phenotype, Genotype, and Comparison to Non-FGF23-Mediated Forms.

    Karlekar MP, Dodamani MH, Lila A, et al.

    Indian pediatrics 2025; (62(3)):211-216 doi:10.1007/s13312-025-00024-6.

    PMID: 40126839
  9. 9

    X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management.

    Baroncelli GI, Mora S

    Frontiers in endocrinology 2021; (12()):688309 doi:10.3389/fendo.2021.688309.

    PMID: 34421819
  10. 10

    Rickets guidance: part II-management.

    Haffner D, Leifheit-Nestler M, Grund A, Schnabel D

    Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.

    PMID: 35352187
  11. 11

    Two variants in SLC34A3 in a patient with X-linked hypophosphatemia: a diagnostic and therapeutic dilemma.

    Sharova M, Klimova E, Filatova A, et al.

    Pediatric nephrology (Berlin, Germany) 2026; doi:10.1007/s00467-026-07520-2.

    PMID: 42684400

This page explains the biology and treatment implications of HHRH and NPHLOP1 for informational purposes only and does not constitute medical advice. Do not change phosphate or vitamin D treatment without speaking with your prescribing clinician or a metabolic-bone specialist.